🏅 FDA Orphan Designation
Truseltiq
infigratinib
Manufacturer: QED Therapeutics, Inc.
Indicated for:
FDA-Approved Indications (1)
Combined hepatocellular carcinoma and cholangiocarcinomaOrphan Designation
Treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected…
Indications & Usage
Treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. (Indication withdrawn 5/16/2024)
💙 Support Programs
View all →Truseltiq
QED Therapeutics, Inc.
Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.
Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.